Medication

Search for

Medication research papers

Factors associated with the development of impulse compulsive disorders in Parkinson patientsConclusion: The use of DA therapy in the treatment of PD patients should be carefully monitored, especially in younger male patients who exhibit early signs of parkinsonian symptoms. As such, it is crucial for physicians to adjust DA dosages while also seeking alternative treatments to avoid the risk of ICD while on DAs. 21 February 2013
Levodopa-Induced Dyskinesias in Tyrosine Hydroxylase DeficiencyAlthough l-dopainduced dyskinesias in tyrosine hydroxylase deficiency are phenomenologically similar to those that occur in Parkinson's disease, they are different in a number of other respects, suggesting intrinsic differences in the pathophysiologic basis of l-dopainduced dyskinesias in the 2 conditions. 06 February 2013
fMRI changes in cortical activation during task performance with unaffected hand partially reverse after ropinirole treatmentResults indicate that in PD patients changes in cortical activation precede the onset of motor symptoms in the clinically unaffected side and are partially reversed by chronic administration of long acting dopamine agonist ropinirole. 01 February 2013
Rest energy expenditure in Parkinson's disease: Role of disease progression and dopaminergic therapyThis cross-sectional study aimed to ascertain the relationship between rest energy expenditure (REE), PD duration, Hoehn & Yahr (H&Y) stage, drug therapy and body mass index (BMI), in order to determine possible predictors of weight loss. 01 February 2013
Impact of discontinuing tremor suppressing medications following thalamic deep brain stimulationBilateral deep brain stimulation effectively eliminated the need for tremor suppressing medications, while unilateral stimulation was not as effective in reducing medication usage. Clinicians and patients should be aware that discontinuation of primidone after surgery may worsen tremor in unilateral deep brain stimulation cases, but discontinuation will not likely impact quality of life. 01 February 2013
Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesiaLevodopa-induced dyskinesia in patients with Parkinson's disease (PD) has been shown to be associated with an abnormal plasticity in the motor cortex. Authors investigated whether changes in the excitability of inhibitory and excitatory motor circuits could underlie maladaptive mechanisms associated with dyskinesia. 01 February 2013
Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum functionThe authors investigated the hypothesis that variation in endogenous dopamine (DA) across brain regions explains dissimilar effects of dopaminergic therapy on aspects of cognition in early Parkinson's disease (PD). Extensive degeneration of DA-producing cells in the substantia nigra cause dorsal striatum (DS) DA deficiency and movement abnormalities. 01 February 2013
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trialsHere, authors review these RCTs to highlight the potential nondopaminergic pharmacological therapies for treatment of motor features of PD. Nondopaminergic drugs are not expected to replace dopaminergic strategies, but further development of these drugs will likely yield novel approaches with positive clinical implications. 01 February 2013
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's diseaseThe pooled data from the safinamide groups failed to reach statistical significance for the primary endpoint of median time from baseline to additional drug intervention. Post-hoc analyses indicate that safinamide 100 mg/day may be effective as add-on treatment to DA in PD. 01 February 2013
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegenerationIn the present study, the authors sought to determine several other common dietary phenolics, namely, tea catechins [(+)-catechin and ()-epicatechin] and a representative flavonoid (quercetin), for their ability to modulate L-DOPA methylation and to protect against oxidative hippocampal injury. 01 February 2013

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ « Previous | Next » ]